Skip to main content
. 2013 Jul 26;8(7):e70432. doi: 10.1371/journal.pone.0070432

Figure 3. pPDGFRβ kinase domain and pLRP1-ICD compete for SHP-2 binding.

Figure 3

(a,b) Increasing concentrations of GST:pLRP1-ICD were incubated with microtiter wells coated with SHP-2 in the presence of 0, 20, 60 and 180 nM pPDGFRβ KD (a) or sPDGFr (b). Bound GST:pLRP1-ICD was detected with anti-GST antibody. Curves in (a) show best fits to a single class of sites using non-linear regression analysis. The KD values at each concentration are significantly different (p = 0.0007, Students t test). (c) Percent binding, normalized to 0 nM pPDGFRβ, of GST:pLRP1-ICD (100 nM) binding to SHP-2 in the presence of 20, 60 and 180 nM pPDGFRβ KD. (*, p = 0.0024; **p<0.0001, Students t test).